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dementia, Alzheimer's disease (AD). Cardiovascular risk factors such as hyperlipidaemia, hypertension 
and type 2 diabetes have attracted attention as potential targets in the prevention of dementia. The 
present review aims to provide a concise overview of the recent advances linking vascular disease with 
dementia (with a particular focus on AD) and to examine the evidence for efficacy, where possible, for 
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ABSTRACT 
The incidence of dementia is increasing dramatically with the ageing population. Increasing 
evidence indicates that vascular disease is associated with cognitive decline and with the most 
common form of dementia, Alzheimer's disease (AD). Cardiovascular risk factors such as 
hyperlipidaemia, hypertension and type 2 diabetes have attracted attention as potential targets 
in the prevention of dementia. The present review aims to provide a concise overview of the 
recent advances linking vascular disease with dementia (with a particular focus on AD) and to 
examine the evidence for efficacy, where possible, for utilising vascular pharmacotherapy as a 
treatment option for dementia. 
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Introduction 
An overview of dementia 
The world population is getting older. The trend has accelerated over recent decades because 
of two main contributing factors: increased life expectancy due to improved medical 
knowledge and a continuing decline in birth rates (particularly in developed countries). 
Current estimates indicate that over half a billion people are aged over 60 years, a number 
predicted to double by 2030 [1]. It is further estimated that nearly 25 million people currently 
have dementia and this number is predicted to treble by 2040 [2]. Prevalence studies 
consistently show a doubling in dementia cases every 5 years from age 60, from about 1% at 
age 60-65 to over 40% at age 90 years. The incidence of dementia is also rising exponentially 
from the same age to reach 70 new cases per 1000 person-years in the oldest old [3,4]. 
Population ageing is a worldwide phenomenon and its associated dementia epidemic clearly 
has important public health implications. 
 
Dementia is a progressive neurodegenerative brain disorder with many clinical presentations 
caused by multiple possible underlying aetiologies, rather than a unitary disease. Current 
clinical diagnostic criteria for the major dementia syndromes emphasize the following 
essential features: (i) development of multiple cognitive disturbance that may include memory 
impairment, aphasia (loss of the ability to articulate ideas or comprehend spoken or written 
language), apraxia (loss of the ability to perform coordinated movements or manipulate 
objects in the absence of motor or sensory impairment), agnosia (the inability to recognize 
common objects, persons, or sounds, in the absence of perceptual disability) or executive 
dysfunctions, (ii) the cognitive deficits of sufficient severity to cause impairment in 
occupational or social functioning, and, (iii) the cognitive deficits must represent a decline 
from a previously higher level of functioning. Underlying these definitions is the progressive 
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nature of dementia. In the population of people over the age of 65, Alzheimer’s disease (AD) 
accounts for up to two thirds of all cases of dementia. Together with vascular dementia (VaD) 
and dementia with Lewy bodies, they account for about 90% of all dementia cases. In 
dementia cases with onset before the age of 65, frontotemporal dementia (FTD) is the second 
most common form after AD. The typical clinical presentation of each dementia type depends 
on the location of the predominant pathology; memory in AD, executive function and speed 
of information processing in VaD, movement control and executive function in dementia with 
Lewy bodies, and behaviour and/or language in FTD. 
 
It is important to note that significant clinical overlap exists across dementia types. About a 
third of AD patients present with significant executive dysfunctions and others exhibit early 
language disturbance, rather than the typical memory deficit [5-7]. Similarly, some FTD 
patients show early and severe episodic memory deficits [8]. As such, a proportion of patients 
who meet clinical criteria for one dementia type (e.g. AD) will also meet clinical criteria for a 
second, or even a third, dementia syndrome. It is also recognised that concordance between 
clinical diagnosis and neuropathology remains suboptimal. For example, a proportion of 
patients show brain pathology at postmortem that is different to their clinical diagnosis, or 
show multiple pathologies [9,10]. Adding further complexity to the clinical diagnosis, mixed 
presentations due to co-existing pathologies become more common with increasing age 
[11,12]. 
 
Familial dementia  
Most cases of dementia are sporadic with no clearly identified aetiology. In about 10% of 
cases, however, genetic mutations causing dementia, in particular AD and FTD, have been 
5 
identified. In AD, causative mutations have been identified in the amyloid precursor protein, 
presenilin-1 and presenilin-2 genes [13-16]. Mutations in the tau, progranulin, as well as a 
couple of less frequent genes are associated with FTD [17]. Cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is associated with 
VaD and caused by mutations on the notch 3 gene [18]. Approximately 10% of AD cases are 
thought to be genetically determined whereas 20-50% of all cases of FTD are estimated to be 
caused by gene mutations transmitted in an autosomal dominant fashion [19]. It is also clear 
that other cases with a strong family history of dementia exist without the known mutations. 
These families, affected over several generations, suggest the contribution of other genes as 
yet to be determined or other modes of genetic transmissions. 
 
Vascular risk factors and dementia 
Epidemiological studies have identified a number of risk factors associated with increased 
risk of sporadic forms of dementia, with age remaining the strongest predictor of most 
common forms of dementia. Additional dementia risk factors identified are associated with 
diabetes, cardiovascular disease, the metabolic syndrome and cerebrovascular disease and 
these include hypercholesterolaemia, hypertension, obesity, smoking, high alcohol 
consumption and high saturated fat intake [4,20]. There is mounting evidence that the 
presence of a number of these risk factors during midlife is predictive of increased dementia 
risk in later years [20-24]. Given that there is currently no curative or disease-modifying 
treatment for the major causes of dementia (i.e. AD and VaD), treatment of the vascular risk 
factors in order to reduce dementia risk or delay its onset represents a plausible approach to 
reduce the burden of disease. Lifestyle changes (e.g. smoking cessation, dietary change, 
increased physical activity, reduced alcohol consumption) are the most obvious preventive 
measures; however, these changes are not always easy to achieve. A number of 
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pharmacological/bioactive agents aimed at reducing vascular risk factors have recently been 
suggested as potential options for the prevention of dementia; these are summarised below. 
 
Hypertension – antihypertensive therapies 
Results from independent studies indicate that midlife hypertension is associated with 
increased risk for the development of cognitive impairment and dementia later in life [25,26]. 
It is well established that hypertension is associated with atherosclerosis of larger vessels and 
hypertensive subjects with cerebrovascular disease have an increased risk of recurrent stroke. 
Evidence indicates that hypertension also impacts on small blood vessel integrity, by reducing 
the resistance of the arteriole wall which will predispose to rupture and result in cerebral 
haemorrhage and concomitant cerebral damage (i.e. small vessel disease). In addition, it is 
likely that hypertension induces cognitive decline in the elderly due to its prolonged negative 
effect on cerebral arterial luminal diameter which results in hypoperfusion. This effect is 
greatest in brain regions fed by distal branches (e.g. deep brain nuclei, hippocampus, 
watershed areas), some of which are critical for memory function. These conditions could 
also contribute to cognitive decline and dementia. Based on the association of hypertension 
with dementia and the postulated mechanisms that may explain this link, the effects of blood 
pressure lowering on the development of cognitive impairment and dementia has been 
addressed in several studies. Recent studies indicate that blood pressure lowering reduces the 
risk of cognitive decline and dementia associated with recurrent stroke in patients with 
cerebrovascular disease [27]. In contrast, a systematic review of studies of blood pressure 
lowering in 12,091 hypertensive patients without apparent prior cerebrovascular disease 
concluded that there was no convincing evidence that blood pressure lowering prevents the 
development of cognitive impairment or dementia [28]. Two excellent recent reviews on this 
subject highlight the potential for variables, such as the type and combination of 
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antihypertensive treatment, the level of hypertension reduction (which can involve 
overshooting and concomitant problems with raised limits of cerebral autoregulation) and 
comorbidities, such as renal insufficiency, to influence the study outcomes related to 
dementia [26,29]. Although it is clear that anti-hypertensive treatment can prevent the 
development of cognitive impairment under specific circumstances, more detailed studies are 
require to confirm which patient groups and what types of medications are appropriate. 
 
Lipid metabolism – cholesterol, statins and n-3 polyunsaturated fatty acids (PUFA) 
In vitro studies and work in animal models suggest that cholesterol homeostasis has an impact 
on pathways that may ultimately regulate the cerebral concentration of the Alzheimer’s 
disease amyloid-β (Aβ) peptide [30-33]. Earlier epidemiological studies suggested an 
association between high serum cholesterol levels and an increased AD risk [34,35]; however, 
it was also shown that hypercholesterolaemia was associated with protection for dementia 
(including AD) in the elderly (>75 years) [36]. A systematic meta-analysis demonstrated a 
consistent association between high midlife (but not late-life) cholesterol levels and increased 
risk of AD and dementia of any type [37]. In addition, retrospective studies revealed a 
possible reduction in AD/dementia risk in association with use of the cholesterol-lowering 
statins [38,39] as well as a lower burden of neurofibrillary tangles and neuritic plaques (both 
are typical features of AD pathology) in post-mortem neuropathologic assessment [40]. 
Intriguingly, it has also been noted that statin use is associated with lower dementia risk 
independent of its cholesterol lowering effects [38]; thus the mechanism underlying this 
protection is still not clear. Data from prospective studies have so far not provided a clear 
answer regarding the use of statins as a preventive measure for AD; however, very recent 
results from a 9-year study, indicate that use of either lipophilic or non-lipophilic statins (but 
not non-statin cholesterol lowering drugs) was associated with a lower risk of AD (see [41] 
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and references cited therein). This study reinforces the idea that statins may protect against 
AD independently of their impact on serum cholesterol levels. In another recent study 
examining the pleiotropic effects of statins in multiple diseases, a protective effect against 
dementia was observed [42]. The majority of cases were diagnosed with VaD or unspecified 
dementia and the protective effect was similar for AD and non-AD dementia [42]. 
 
It is also important to mention that statins prevent stroke and may decrease cerebral damage if 
therapy is initiated within 24 h of onset of acute ischaemic stroke [43,44]. These effects are 
likely to be mediated at least partially by stabilisation of vulnerable atherosclerotic plaques in 
the aorta and carotid artery thereby reducing the risk of thromboembolism; although several 
pleiotropic effects (including antithrombotic actions and direct actions that improve 
endothelial function, e.g. increasing nitric oxide bioavailability) have also been postulated 
[43,44]. It is also conceivable that statins may afford protection in the setting of “multi-infarct 
dementia” where multiple cerebral microinfarcts may lead to cerebral hypoperfusion which 
has been suggested to contribute to cognitive decline in normal brain ageing, VaD and AD 
[45-49]. We are not aware of studies that have directly investigated the effect of statin 
treatment on cerebral microinfarct formation but this would seem to be an important area to 
investigate. While more research is required, it appears that statins may yet provide a 
plausible therapeutic option to reduce risk for AD and possibly VaD and other non-AD 
dementias. Other studies related to cholesterol homeostasis and AD, have revealed that 
enzymatically oxidised forms of cholesterol (oxysterols), and synthetic compounds that 
activate the nuclear hormone receptor LXRα, inhibit cerebral Aβ accumulation in animal 
studies and it is predicted that compounds that may regulate LXRα-inducible genes to treat 
AD in humans may follow [50]. 
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Another area of lipid metabolism that has been the focus of several studies related to 
preventive strategies for dementia involves the administration of n-3 PUFA that are present at 
high concentrations in fish oils. Epidemiological studies, both cross-sectional and 
longitudinal, have yielded conflicting results regarding an association between n-3 PUFA 
consumption and cognitive decline (see [51,52] and references cited therein). In recent short 
term (6 months) randomised, double-blind, placebo-controlled studies of AD patients or 
normal elderly subjects, supplementation with n-3 PUFA (up to 1.8 g/day) did not result in 
marked improvements in neuropsychiatric symptoms in the patients or in enhanced cognitive 
performance in the cognitively healthy elderly subjects [52,53]. Although it appears that n-3 
PUFA supplements may not be helpful, at least in the short term, previous studies have 
reported that high concentrations of n-3 PUFA in the blood is associated with a lower risk of 
cognitive decline [54-56]. This may be associated with long-term anti-inflammatory actions 
(e.g., decreased production of pro-inflammatory cytokines from peripheral blood 
mononuclear cells) or blood pressure lowering effects in hypertensive subjects that would be 
predicted to decrease the risk of cognitive decline and potentially reduce the risk of 
developing AD in specific sub-groups of the population [57]. 
 
Type 2 diabetes - peroxisome proliferator-activated receptor gamma (PPARγ) agonists 
and insulin 
Subjects with non-insulin-dependent diabetes mellitus (commonly referred to as type 2 
diabetes) in the Rotterdam Study were found to have a 3-fold increased risk of developing 
dementia [58]. Although this risk was strongly associated with VaD, similar associations were 
also observed for AD [58]. It has also been reported that diabetes in midlife is a strong 
predictor of dementia later (3 decades) in life [59]. Several epidemiological studies have now 
confirmed an association of type 2 diabetes (and its precursor, insulin resistance syndrome) 
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with increased risk for VaD and AD (see [60] and references cited therein). Interestingly, in a 
study of twins in which the possible association of multiple vascular risk factors (diabetes, 
hypercholesterolaemia, hypertension and elevated body mass index) with cognitive decline 
was examined, only diabetes was significantly correlated with accelerated cognitive decline 
[61]. As discussed in detail by Biessels and Kapelle [62] and Martins et al. [60], diabetic 
cerebrovascular disease and abnormal cerebral glucose utilisation have been implicated as 
causative factors in AD associated with type 2 diabetes. In addition, pathological studies in 
humans have demonstrated increased microvascular infarcts in dementia patients with 
diabetes compared with dementia patients without diabetes [63]. Strong evidence from animal 
studies (streptozotocin-treated rats) shows that diabetes progressively increases blood-brain 
barrier (BBB) permeability [64]. Insulin treatment appears to be a useful approach to resolve 
in part the altered BBB permeability in the early stages of disease in the rat model [64]. 
Increased BBB permeability may also be related to cerebral microvascular pathology in 
humans [64,65]. In diabetic patients with dementia, however, treatment of hyperglycaemia 
(with insulin and/or sulfonylureas and/or metformin) increased the number microvascular 
infarcts in deep cerebral structures when compared with untreated diabetic patients with 
dementia [63]. Magnetic resonance imaging (MRI) has provided further evidence for vascular 
damage (infarcts, lacunes and white matter hyperintensities) associated with type 2 diabetes in 
the Honolulu-Asia aging study [66]. Additional studies focusing on the impact that specific 
anti-hyperglycaemic treatments may have on human microvascular pathology are required to 
clarify the complex association of diabetic microvascular/BBB dysfunction with dementia. 
 
Largely based on epidemiological evidence, additional therapies that are used to treat type 2 
diabetes are under investigation for their protective potential in AD. The major therapeutic 
approach under examination in this context is the thiazolidinedione (TZD) class of 
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compounds that are agonists for the nuclear receptor, PPARγ [67]. PPARγ agonists regulate 
lipid metabolism, energy metabolism, insulin sensitivity and may also act as anti-
inflammatory agents and modulators of Aβ production and/or clearance [67-69]. There is 
strong evidence that the PPARγ agonist rosiglitazone enhances attention and memory in 
patients with mild to moderate AD [70]. Intriguingly, patients possessing an apoE4 allele do 
not gain therapeutic potential from rosiglitazone [70]. More specifically, using the 
Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score as a primary 
efficacy endpoint, APOE ε4-negative patients showed improvement in cognitive function 
after 24 weeks of rosiglitazone treatment whereas APOE ε4-positive patients showed no 
improvement overall [70]. The precise mechanism(s) by which TZDs may improve memory 
and cognition in dementia patients remains an open question. Pioglitazone is thought to pass 
the BBB to some degree while rosiglitazone is suggested to mediate its protective effects in 
the peripheral circulation, although there is some evidence from mouse studies to suggest 
small amounts of rosiglitazone may also enter the brain (see [67] and references cited 
therein). In addition to the possible beneficial effects of TZDs on insulin sensitivity, 
inflammation and Aβ homeostasis, peripheral lipoprotein metabolism is also targeted. In this 
context, pioglitazone and rosiglitazone appear to have quite distinct effects with pioglitazone 
treatment associated with significant improvements in plasma triglyceride, HDL cholesterol 
and LDL particle size and concentration as compared with rosiglitazone [71,72]. Potential 
differences in TZD efficacy related to memory and cognition in humans remains to be 
established. Studies are currently underway that will shed further light on this promising 
approach (14 clinical trials listed, 13 using rosiglitazone and one using pioglitazone, at the US 
clinical trials website [www.clinicaltrials.gov] at the time of writing).  
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It has also been proposed that insulin resistance may play a direct role in AD [60,73]. Diabetic 
complications associated with cerebrovascular accumulation of advanced glycation end 
products (AGEs) represent one plausible explanation for this association. Another more direct 
mechanism involves a role for insulin in CNS energy metabolism. For example, insulin-
sensitive glucose transporters are expressed in brain regions that are associated with memory 
and learning and insulin treatment can profoundly modulate cognitive function under 
experimental settings [74,75]. In order to examine the direct impact of central insulin 
administration on memory, recent studies have assessed the impact intranasal insulin delivery 
has on cognitive function in humans [76-78]. The data indicate that intranasal insulin 
administration may improve attention in patients with early AD or mild cognitive impairment 
and that verbal memory may also be improved but only in subjects who do not carry an apoE4 
allele. Interestingly, subjects who carry an apoE4 allele demonstrated a relative decline in 
verbal memory with insulin administration [77]. Clearly, further studies are required to 
confirm which patient groups would benefit from intranasal insulin administration. 
 
 
Cerebrovascular inflammation – nonsteroidal anti-inflammatory drugs (NSAIDs) 
Cortical neuroinflammation is a key feature of AD and increased levels of luminal Aβ may 
permeabilize the blood-brain barrier (BBB), increasing vasoconstriction of arterial vessels, 
and thereby contributing to chronic inflammation [79]. Cerebral amyloidosis is highly 
prevalent in AD and VaD and it has been suggested that anti-inflammatory medications may 
alleviate these problems [80-83]. Several epidemiological studies have shown that the 
prevalence of AD is reduced in people using NSAIDs (see [81,84-86] and references cited 
therein). Interestingly, the protective effect of NSAID use appears to be observed only in 
subjects who carry an apoE4 allele [85]. Based on the epidemiological studies and the 
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demonstrated anti-amyloidogenic actions of specific NSAIDs in animal studies (e.g. [81]), a 
number of prospective studies aiming to assess the efficacy of NSAIDs in the prevention of 
AD or slowing of cognitive decline in persons at risk of developing dementia have been 
undertaken. Unfortunately, the results from a large randomised, controlled trial of the 
NSAIDs naproxen and celecoxib have shown that anti-inflammatory treatment did not 
improve cognitive function in subjects with a family history of AD and the final 
recommendation was that these specific anti-inflammatory agents should not be used for the 
prevention of AD [87]. It is possible that the follow-up period (1 to 4 years) was not sufficient 
to detect a benefit in this study (i.e. since AD has a long sub-clinical phase in which exposure 
of a preventative therapeutic may be required). Alternatively, because there was weak 
evidence for a detrimental effect of naproxen [87], it maybe that neuroinflammation 
demonstrated by microglial activation maybe beneficial in terms of responding appropriately 
to Aβ deposition and clearance [88]. 
 
Vitamin supplements 
Several lines of evidence led to the proposal that dietary supplementation with vitamin C, 
vitamin E or the B group vitamins, folate, B6 and B12, may reduce cognitive decline in the 
elderly and afford protection for AD [89-91]. In general, the potential protective action of 
vitamins C and E is speculated to be via reduction of oxidative stress that is associated with 
AD [92]; whereas the B vitamins are predicted to offer benefit by reducing the concentration 
of the potentially harmful amino acid homocysteine [90]. Epidemiological studies suggest an 
association between AD risk and low plasma levels of vitamin E and high levels of 
homocysteine [93,94]. Very similar proposals for antioxidant vitamin supplementation and 
homocysteine reducing strategies have been suggested for the treatment of vascular diseases 
including atherosclerosis [95]. It now seems that neither antioxidant vitamin supplements or 
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reductions in plasma homocysteine concentrations provide a general benefit for vascular 
disease [96-99]. Emerging data also suggest that supplementation with these vitamins may not 
be useful for the treatment of dementia. Prospective trials and meta-analyses of the literature 
failed to detect consistent therapeutic benefits with vitamin E and vitamin C supplementation 
in terms of risk for developing AD and non-AD dementia [100-102]. Similarly, recent data 
suggest that supplementation with B group vitamins to reduce plasma homocysteine levels 
does not have an impact on cognitive decline or AD [103-106]. Although it remains possible 
that in vitamin deficient states, dietary supplements may provide some benefit, it is becoming 
increasingly clear that dietary supplementation with the abovementioned vitamins does not 
offer a therapeutic benefit for the prevention of cognitive decline or AD. 
 
Conclusions 
There is substantial epidemiological data indicating that vascular disease may be causative in 
dementia including AD. In addition, risk factors for both peripheral and microvascular 
diseases (including atherosclerosis and hypertension) and diabetes also increase risk for AD. 
Advances in the development of biomarkers (e.g. using brain imaging techniques) for 
cerebrovascular disease continues to provide insights into the complex interplay between 
vascular disease and both AD and non-AD dementia [107,108]. Despite strong rationale for 
therapeutic targeting of vascular disease/vascular risk factors as a potential strategy to prevent 
the onset of AD or at least slow cognitive decline in the elderly [109-113], prospective studies 
so far have not generally supported the idea that vascular pharmacotherapy can be considered 
as an efficacious option for the treatment or prevention of dementia in the general population. 
It is clear, however, that certain sub-populations may indeed benefit from some of the 
therapies (e.g. subjects who do not posses an apoE4 allele benefit from rosiglitazone and from 
intranasal insulin administration). It may also be the case that timing and duration of 
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therapeutic administration is the key to success since AD and non-AD dementias are thought 
to have a long sub-clinical phase (i.e. sometimes 20 years or more). Although it appears that 
there is no vascular panacea that will help in the fight against the increasing prevalence of 
dementia, the current evidence indicates that specific sub-groups in the population will benefit 
from selected vascular pharmacotherapies and the challenge now is to define accurately the 
genetic, age and risk-factor profiles of those individuals who will benefit from such 
intervention. 
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